23 March 2021
Kanabo Group Plc
"Kanabo" or the "Company"
PUBLICATION OF RESEARCH NOTE
Kanabo Group Plc (LSE: KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, welcomes the publication of an analyst report by Equity Development Limited, an experienced investment research and advisory company.
A copy of the report is available at:
https://www.equitydevelopment.co.uk/research/driven-by-safety-and-precision-1
For more information, please contact:
Kanabo Group +972 523173633
Meirav Horn, CFO
Peterhouse Capital Limited +44 (0)20 7469 0930
Eran Zucker / Lucy Williams / Allie Feuerlein
About KANABO GROUP PLC
Kanabo aims to create a new standard in the medical cannabis industry by building an ecosystem that improves the well-being of millions around the world by providing an alternative solution to the smoking of medicinal cannabis flowers. With a focus on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, Kanabo has conducted extensive Research & Development in order to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions.